Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245336 · ClinicalTrials.gov registry record · Phase 3
Study of Recombinant Human Thrombin for Bleeding During Surgery
A Phase 3 study, sponsored by ZymoGenetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 401
- Enrollment target
NCT00245336 is a Phase 3 study that has completed, run by ZymoGenetics. The registered enrollment target is 401 participants.
The verdict
NCT00245336, a Phase 3 study, has completed, sponsored by ZymoGenetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 401 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether recombinant human Thrombin (rhThrombin) is effective in stopping bleeding during surgery, in comparison with bovine thrombin.
Interventions
- BIOLOGICAL rThrombin
- DRUG bovine thrombin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245336
The ClinicalTrials.gov registry entry for NCT00245336 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 401 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZymoGenetics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rThrombin is the first listed.
NCT00245336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00245336 about?
NCT00245336 is a clinical study titled "Study of Recombinant Human Thrombin for Bleeding During Surgery". The purpose of this study is to determine whether recombinant human Thrombin (rhThrombin) is effective in stopping bleeding during surgery, in comparison with bovine thrombin.
What is the current status of trial NCT00245336?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 401 participants. The study started on 2005-10. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00245336?
The interventions under investigation include: rThrombin (BIOLOGICAL), bovine thrombin (DRUG).
Who is sponsoring clinical trial NCT00245336?
This trial is sponsored by ZymoGenetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.